The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer

Cancer Causes and Control

Volumn 22, Issue 3, 2011, Pages 417-426

  Fowke, Jay H ^a   Motley, Saundra S ^a   Barocas, Daniel A ^a   Cookson, Michael S ^a   Concepcion, Raoul ^a,b   Byerly, Susan ^a   Smith Jr , Joseph A ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b Urology Associates   (United States)

Author keywords

Bias; Prostate cancer; Prostate volume; PSA; Statin

Indexed keywords

ALFUZOSIN; AMLODIPINE; ATENOLOL; ATORVASTATIN; COLESTYRAMINE; ENALAPRIL; EZETIMIBE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; GLITAZONE DERIVATIVE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LISINOPRIL; METFORMIN; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; PROSTATE SPECIFIC ANTIGEN; ROSUVASTATIN; SIMVASTATIN; SULFONYLUREA DERIVATIVE; TAMSULOSIN;

ADULT; AGED; ARTICLE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DIGITAL RECTAL EXAMINATION; DISEASE SEVERITY; DRUG USE; GLEASON SCORE; HUMAN; HYPERLIPIDEMIA; INTERVIEW; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN BLOOD LEVEL; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; DIGITAL RECTAL EXAMINATION; EARLY DETECTION OF CANCER; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS;

EID: 79955761349     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-010-9713-4     Document Type: Article

References (33)

1. Moyad MA (2004) Improving overall men's health and potentially reducing the risk of certain cancers via serum markers and risk assessment for coronary heart disease. Urol Oncol: Semin Orig Investig 22:485-489 (Pubitemid 43193738)
2. Platz EA, Till C, Goodman PJ et al (2009) Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 18:2807-2813
3. Hebert PR, Gaziano JM, Chan KS, Hennekens CH (1997) Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 278:313-321 (Pubitemid 27339660)
4. Jain MK, Ridker PM (2005) Anti-inflammatory effects of statins: Clinical evidence and basic mechanisms. Nat Rev Drug Discov 4:977-987
5. Murtola TJ, Tammela TL, Lahtela J, Auvinen A (2007) Cholesterol- lowering drugs and prostate cancer risk: A population-based case-control study. Cancer Epidemiol Biomarkers Prev 16:2226-2232 (Pubitemid 351196353)
6. Farwell WR, Scranton RE, Lawler EV et al (2008) The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 100:134-139 (Pubitemid 351480564)
7. Boudreau DM, Yu O, Buist DS, Miglioretti DL (2008) Statin use and prostate cancer risk in a large population-based setting. Cancer Causes Control 19:767-774
8. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE (2007) Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 16:2213-2217 (Pubitemid 351196351)
9. Platz EA, Leitzmann MF, Visvanathan K et al (2006) Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 98: 1819-1825 (Pubitemid 46017933)
10. Breau RH, Karnes RJ, Jacobson DJ et al (2010) The association between statin use and the diagnosis of prostate cancer in a population based cohort. J Urol 184:494-500
11. Flick ED, Habel LA, Chan KA et al (2007) Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev 16:2218-2225 (Pubitemid 351196352)
12. Friedman GD, Flick ED, Udaltsova N, Chan PD, Quesenberry CP, Habel LA (2008) Screening statins for possible carcinogenic risk: Up to 9 years of follow-up of 361CÇë859 recipients. Pharmacoepidem Drug Safe 17:27-36 (Pubitemid 351166615)
13. Murtola TJ, Tammela TL, Maattanen L et al. (2010) Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. Int J Cancer
14. Banez LL, Klink JC, Jayachandran J et al (2010) Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy. Cancer Epidemiol Biomarkers Prev 19:722-728
15. Agalliu I, Salinas CA, Hansten PD, Ostrander EA, STanford JL (2008) Statin use and risk of prostate cancer: Results from a population-based epidemiologic study. Am J Epidemiol 168: 250-260 (Pubitemid 352019786)
16. Mondul AM, Selvin E, De Marzo AM, Freedland SJ, Platz EA (2010) Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001-2004. Cancer Causes Control
17. Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ (2008) The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst 100:1511-1518
18. Thompson IM, Goodman PJ, Tangen CM et al (2003) The influence of Finasteride on the Development of Prostate Cancer. N Engl J Med 349:213-222
19. Mills IW, Crossland A, Patel A, Ramonas H (2007) Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement. Eur Urol 52:503-509 (Pubitemid 46963443)
20. Fowke JH, Matthews CE (2010) PSA and body composition by dual X-ray absorptiometry (DXA) in NHANES. Prostate 70: 120-125
21. Fowke JH, Motley S, Smith JA, Jr., Cookson MS, Concepcion R, Chang SS (2008) Association between non-steroidal antiinflammatory drugs, PSA, and Prostate Volume. J Urol
22. Werny DM, Saraiya M, Gregg EW (2006) Prostate-specific antigen values in diabetic and nondiabetic US Men, 2001-2002. Am J Epidemiol 164:978-983 (Pubitemid 44729839)
23. Loeb S, Kan D, Helfand BT, Nadler RB, Catalona WJ (2009) Is statin use associated with prostate cancer aggressiveness? BJU Int
24. Algotar AM, Thompson PA, Ranger-Moore J et al. (2010) Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity. Prostate
25. Hall SA, Page ST, Travison TG, Montgomery RB, Link CL, McKinlay JB (2007) Do statins affect androgen levels in men? Results from the Boston area community health survey. Cancer Epidemiol Biomarkers Prev 16:1587-1594 (Pubitemid 47294823)
26. Graaf MR, Richel DJ, van Noorden CJ, Guchelaar HJ (2004) Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 30: 609-641 (Pubitemid 39451828)
27. Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostatic hyperplasia with age. J Urol 132:474-479 (Pubitemid 14026148)
28. Fowke JH, Motley SS, Cookson MS et al (2006) The association between body size, prostate volume and prostate-specific antigen. Prostate Cancer Prostatic Dis 10:137-142
29. Michel MC, Heemann U, Schumacher H, Mehlburger L, Goepel M (2004) Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol 172:1390-1393 (Pubitemid 39249727)
30. Parsons JK, Bergstrom J, Barrett-Connor E (2008) Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community- dwelling men. BJU Int 101:313-318
31. Nelson WG, DeMarzo AM, DeWeese TL, Isaacs WB (2004) The role of inflammation in the pathogenesis of prostate cancer. J Urol 172:S6-S11
32. Sreekumar A, Poisson LM, Rajendiran TM et al (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457:910-914
33. Moyad MA, Merrick GS, Butler WM et al (2005) Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology 66:1150-1154 (Pubitemid 41797279)